| pubmed-article:15569374 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15569374 | lifeskim:mentions | umls-concept:C0007600 | lld:lifeskim |
| pubmed-article:15569374 | lifeskim:mentions | umls-concept:C0546837 | lld:lifeskim |
| pubmed-article:15569374 | lifeskim:mentions | umls-concept:C0334227 | lld:lifeskim |
| pubmed-article:15569374 | lifeskim:mentions | umls-concept:C0281603 | lld:lifeskim |
| pubmed-article:15569374 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:15569374 | pubmed:dateCreated | 2004-11-30 | lld:pubmed |
| pubmed-article:15569374 | pubmed:abstractText | Flavopiridol is a synthetic flavone that has shown an antitumor effect against several cancers. Here, we investigated the in vitro effect of flavopiridol alone and the combined effect of low-dose flavopiridol plus radiation on esophageal squamous cell carcinoma cell lines. Esophageal squamous cell carcinoma cell lines (TE8, TE9 and KE4) were exposed to flavopiridol (0.05-400 nmol/L) for 48 h. Growth inhibition was evaluated by MTT assay, cell cycle distribution was determined by flow cytometry, and cyclin D1, Bcl-2 and Rb protein expression was detected by Western blotting. The effect of 0.05 nmol/L flavopiridol as a radio-sensitizer was determined by clonogenic assay. The IC50 was approximately 110-250 nmol/L. Exposure to 0.05 nmol/L flavopiridol for 48 h increased the G2/M population, while 300 nmol/L increased the G1 population. At a concentration of 300 nmol/L, nuclear fragmentation and chromatin condensation were observed in all three cell lines. Exposure to 300 nmol/L flavopiridol decreased the levels of cyclin D1 and Rb protein in all three cell lines and Bcl-2 protein was also decreased in TE8 and KE4 cells. Moreover, exposure to 0.05 nmol/L flavopiridol slightly decreased the levels of cyclin D1, Rb and Bcl-2 protein in KE4 cells. Flavopiridol treatment (0.05 nmol/L) enhanced the radio-sensitivity in all three cell lines. Low-dose flavopiridol augmented the response of esophageal squamous cell carcinoma cell lines to radiation. Administration of a low dose of flavopiridol could be a potent new therapeutic approach for improving the efficacy of radiotherapy against esophageal cancer. | lld:pubmed |
| pubmed-article:15569374 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15569374 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15569374 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15569374 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15569374 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15569374 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15569374 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15569374 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15569374 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15569374 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15569374 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15569374 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15569374 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15569374 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15569374 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15569374 | pubmed:issn | 1120-8694 | lld:pubmed |
| pubmed-article:15569374 | pubmed:author | pubmed-author:SatoSS | lld:pubmed |
| pubmed-article:15569374 | pubmed:author | pubmed-author:SuganoMM | lld:pubmed |
| pubmed-article:15569374 | pubmed:author | pubmed-author:TsurumaruMM | lld:pubmed |
| pubmed-article:15569374 | pubmed:author | pubmed-author:KajiyamaYY | lld:pubmed |
| pubmed-article:15569374 | pubmed:author | pubmed-author:IwanumaYY | lld:pubmed |
| pubmed-article:15569374 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15569374 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:15569374 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15569374 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15569374 | pubmed:pagination | 338-44 | lld:pubmed |
| pubmed-article:15569374 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15569374 | pubmed:meshHeading | pubmed-meshheading:15569374... | lld:pubmed |
| pubmed-article:15569374 | pubmed:meshHeading | pubmed-meshheading:15569374... | lld:pubmed |
| pubmed-article:15569374 | pubmed:meshHeading | pubmed-meshheading:15569374... | lld:pubmed |
| pubmed-article:15569374 | pubmed:meshHeading | pubmed-meshheading:15569374... | lld:pubmed |
| pubmed-article:15569374 | pubmed:meshHeading | pubmed-meshheading:15569374... | lld:pubmed |
| pubmed-article:15569374 | pubmed:meshHeading | pubmed-meshheading:15569374... | lld:pubmed |
| pubmed-article:15569374 | pubmed:meshHeading | pubmed-meshheading:15569374... | lld:pubmed |
| pubmed-article:15569374 | pubmed:meshHeading | pubmed-meshheading:15569374... | lld:pubmed |
| pubmed-article:15569374 | pubmed:meshHeading | pubmed-meshheading:15569374... | lld:pubmed |
| pubmed-article:15569374 | pubmed:meshHeading | pubmed-meshheading:15569374... | lld:pubmed |
| pubmed-article:15569374 | pubmed:meshHeading | pubmed-meshheading:15569374... | lld:pubmed |
| pubmed-article:15569374 | pubmed:meshHeading | pubmed-meshheading:15569374... | lld:pubmed |
| pubmed-article:15569374 | pubmed:meshHeading | pubmed-meshheading:15569374... | lld:pubmed |
| pubmed-article:15569374 | pubmed:meshHeading | pubmed-meshheading:15569374... | lld:pubmed |
| pubmed-article:15569374 | pubmed:meshHeading | pubmed-meshheading:15569374... | lld:pubmed |
| pubmed-article:15569374 | pubmed:meshHeading | pubmed-meshheading:15569374... | lld:pubmed |
| pubmed-article:15569374 | pubmed:meshHeading | pubmed-meshheading:15569374... | lld:pubmed |
| pubmed-article:15569374 | pubmed:meshHeading | pubmed-meshheading:15569374... | lld:pubmed |
| pubmed-article:15569374 | pubmed:meshHeading | pubmed-meshheading:15569374... | lld:pubmed |
| pubmed-article:15569374 | pubmed:meshHeading | pubmed-meshheading:15569374... | lld:pubmed |
| pubmed-article:15569374 | pubmed:meshHeading | pubmed-meshheading:15569374... | lld:pubmed |
| pubmed-article:15569374 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15569374 | pubmed:articleTitle | Flavopiridol as a radio-sensitizer for esophageal cancer cell lines. | lld:pubmed |
| pubmed-article:15569374 | pubmed:affiliation | First Department of Surgery, Juntendo University School of Medicine, Tokyo, Japan. ssato@maz.miinet.or.jp | lld:pubmed |
| pubmed-article:15569374 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15569374 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15569374 | lld:pubmed |
